Int. J. Mol. Sci. 2013, 14(6), 10683-10693; doi:10.3390/ijms140610683
Article

RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study

1 Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), via P. Maroncelli 40, 47014 Meldola (FC), Italy 2 Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), via P. Maroncelli 40, 47014 Meldola (FC), Italy 3 Unit of Biostatistics and Clinical Trials, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), via P. Maroncelli 40, 47014 Meldola (FC), Italy 4 Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), via P. Maroncelli 40, 47014 Meldola (FC), Italy
* Author to whom correspondence should be addressed.
Received: 15 April 2013; in revised form: 9 May 2013 / Accepted: 13 May 2013 / Published: 23 May 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
PDF Full-text Download PDF Full-Text [485 KB, Updated Version, uploaded 24 May 2013 18:51 CEST]
The original version is still available [485 KB, uploaded 23 May 2013 11:39 CEST]
Abstract: Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa®, ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator of nuclear factor-k B ligand (RANK-L)/ Osteoprotegerin (OPG)) and to correlate these with serum N-terminal telopeptide (NTX). The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts by real-time PCR and NTX expression by ELISA in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer. All patients received the standard ZA schedule and were monitored for 12 months. Median baseline values of RANK, RANK-L and OPG were 78.28 (range 7.34–620.64), 319.06 (21.42–1884.41) and 1.52 (0.10–58.02), respectively. At 12 months, the median RANK-L value had decreased by 22% with respect to the baseline, whereas median OPG levels had increased by about 96%. Consequently, the RANK-L/OPG ratio decreased by 56% from the baseline. Median serum NTX levels decreased over the 12-month period, reaching statistical significance (p < 0.0001). Our results would seem to indicate that ZA modulates RANK, RANK-L and OPG expression, thus decreasing osteoclast activity.
Keywords: RANK; RANK-L; OPG; NTX; bone metastases

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Mercatali, L.; Ricci, M.; Scarpi, E.; Serra, P.; Fabbri, F.; Ricci, R.; Liverani, C.; Zanoni, M.; Zoli, W.; Maltoni, R.; Gunelli, E.; Amadori, D.; Ibrahim, T. RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. Int. J. Mol. Sci. 2013, 14, 10683-10693.

AMA Style

Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. International Journal of Molecular Sciences. 2013; 14(6):10683-10693.

Chicago/Turabian Style

Mercatali, Laura; Ricci, Marianna; Scarpi, Emanuela; Serra, Patrizia; Fabbri, Francesca; Ricci, Rossana; Liverani, Chiara; Zanoni, Michele; Zoli, Wainer; Maltoni, Roberta; Gunelli, Erica; Amadori, Dino; Ibrahim, Toni. 2013. "RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study." Int. J. Mol. Sci. 14, no. 6: 10683-10693.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert